Long Grove Pharms Drug Patent Portfolio
Long Grove Pharms owns 1 orange book drug protected by 6 US patents Given below is the list of Long Grove Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10159657 | Norepinephrine compositions and methods therefor | 30 Jan, 2038 | Active |
| US10226436 | Norepinephrine compositions and methods therefor | 30 Jan, 2038 | Active |
| US10420735 | Norepinephrine compositions and methods therefor | 30 Jan, 2038 | Active |
| US10568850 | Norepinephrine compositions and methods therefor | 30 Jan, 2038 | Active |
| US11413259 | Norepinephrine compositions and methods therefor | 30 Jan, 2038 | Active |
| US11602508 | Norepinephrine compositions and methods therefor | 30 Jan, 2038 | Active |
Latest Legal Activities on Long Grove Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Long Grove Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Jun, 2024 | US10888534 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 25 Aug, 2023 | US10568850 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 24 Mar, 2023 | US10420735 (Litigated) |
|
Patent Issue Date Used in PTA Calculation
Critical
| 14 Mar, 2023 | US11602508 |
|
Recordation of Patent Grant Mailed
Critical
| 14 Mar, 2023 | US11602508 |
| Mail Post Card | 09 Mar, 2023 | US11602508 |
|
Email Notification
Critical
| 01 Mar, 2023 | US11602508 |
|
Email Notification
Critical
| 23 Feb, 2023 | US11602508 |
|
Issue Notification Mailed
Critical
| 22 Feb, 2023 | US11602508 |
| Dispatch to FDC | 10 Feb, 2023 | US11602508 |
|
Application Is Considered Ready for Issue
Critical
| 10 Feb, 2023 | US11602508 |
|
Mail Notice of Allowance
Critical
| 06 Feb, 2023 | US11602508 |
|
Issue Fee Payment Verified
Critical
| 06 Feb, 2023 | US11602508 |
|
Issue Fee Payment Received
Critical
| 06 Feb, 2023 | US11602508 |
|
Notice of Allowance Data Verification Completed
Critical
| 01 Feb, 2023 | US11602508 |
Long Grove Pharms's Family Patents
Long Grove Pharms Drug List
Given below is the complete list of Long Grove Pharms's drugs and the patents protecting them.
1. Norepinephrine Bitartrate In 0.9% Sodium Chloride
Norepinephrine Bitartrate In 0.9% Sodium Chloride is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10159657 | Norepinephrine compositions and methods therefor |
30 Jan, 2038
(13 years from now)
| Active |
| US10226436 | Norepinephrine compositions and methods therefor |
30 Jan, 2038
(13 years from now)
| Active |
| US10420735 | Norepinephrine compositions and methods therefor |
30 Jan, 2038
(13 years from now)
| Active |
| US10568850 | Norepinephrine compositions and methods therefor |
30 Jan, 2038
(13 years from now)
| Active |
| US11413259 | Norepinephrine compositions and methods therefor |
30 Jan, 2038
(13 years from now)
| Active |
| US11602508 | Norepinephrine compositions and methods therefor |
30 Jan, 2038
(13 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Norepinephrine Bitartrate In 0.9% Sodium Chloride's drug page